Cargando…

Type I Interferonopathies in Childhood

Type 1 interferonopathy is a novel context reflecting a group of inborn disorders sharing common pathway disturbances. This group of diseases is characterized by autoimmunity and autoinflammation caused by an upregulation of type 1 interferons (IFN)s due to certain genetic mutations. Several feature...

Descripción completa

Detalles Bibliográficos
Autores principales: Haşlak, Fatih, Kılıç Könte, Elif, Aslan, Esma, Şahin, Sezgin, Kasapçopur, Özgür
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175883/
https://www.ncbi.nlm.nih.gov/pubmed/37161741
http://dx.doi.org/10.4274/balkanmedj.galenos.2023.2023-4-78
_version_ 1785040310509764608
author Haşlak, Fatih
Kılıç Könte, Elif
Aslan, Esma
Şahin, Sezgin
Kasapçopur, Özgür
author_facet Haşlak, Fatih
Kılıç Könte, Elif
Aslan, Esma
Şahin, Sezgin
Kasapçopur, Özgür
author_sort Haşlak, Fatih
collection PubMed
description Type 1 interferonopathy is a novel context reflecting a group of inborn disorders sharing common pathway disturbances. This group of diseases is characterized by autoimmunity and autoinflammation caused by an upregulation of type 1 interferons (IFN)s due to certain genetic mutations. Several features are common in most of the diseases in this group, such as vasculitic skin changes, including chilblains, panniculitis, interstitial lung disease, basal ganglion calcifications, neuromotor impairments, epilepsy, stroke, and recurrent fever. Family history and consanguineous marriage are also common. IFN signature is a useful diagnostic tool and is positive in almost all patients with type 1 interferonopathies. Although IFN signature is a sensitive test, its specificity is relatively low. It can also be positive in viral infections and several connective tissue diseases. Therefore, next-generation sequence methods, whole exome sequencing (WES) in particular, are required for the ultimate diagnosis. The optimal treatment regime is still under debate due to a lack of clinical trials. Although high-dose steroids, anti-IL-1 and anti-IL-6 treatments, and reverse transcriptase inhibitors are used, JAK inhibitors are highly promising. Additionally, monoclonal antibodies against IFN-alpha and interferon-α receptor (IFNAR) are currently underway.
format Online
Article
Text
id pubmed-10175883
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-101758832023-05-13 Type I Interferonopathies in Childhood Haşlak, Fatih Kılıç Könte, Elif Aslan, Esma Şahin, Sezgin Kasapçopur, Özgür Balkan Med J Invited Review Type 1 interferonopathy is a novel context reflecting a group of inborn disorders sharing common pathway disturbances. This group of diseases is characterized by autoimmunity and autoinflammation caused by an upregulation of type 1 interferons (IFN)s due to certain genetic mutations. Several features are common in most of the diseases in this group, such as vasculitic skin changes, including chilblains, panniculitis, interstitial lung disease, basal ganglion calcifications, neuromotor impairments, epilepsy, stroke, and recurrent fever. Family history and consanguineous marriage are also common. IFN signature is a useful diagnostic tool and is positive in almost all patients with type 1 interferonopathies. Although IFN signature is a sensitive test, its specificity is relatively low. It can also be positive in viral infections and several connective tissue diseases. Therefore, next-generation sequence methods, whole exome sequencing (WES) in particular, are required for the ultimate diagnosis. The optimal treatment regime is still under debate due to a lack of clinical trials. Although high-dose steroids, anti-IL-1 and anti-IL-6 treatments, and reverse transcriptase inhibitors are used, JAK inhibitors are highly promising. Additionally, monoclonal antibodies against IFN-alpha and interferon-α receptor (IFNAR) are currently underway. Galenos Publishing 2023-05-08 /pmc/articles/PMC10175883/ /pubmed/37161741 http://dx.doi.org/10.4274/balkanmedj.galenos.2023.2023-4-78 Text en ©Copyright 2023 by Trakya University Faculty of Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Balkan Medical Journal published by Galenos Publishing House.
spellingShingle Invited Review
Haşlak, Fatih
Kılıç Könte, Elif
Aslan, Esma
Şahin, Sezgin
Kasapçopur, Özgür
Type I Interferonopathies in Childhood
title Type I Interferonopathies in Childhood
title_full Type I Interferonopathies in Childhood
title_fullStr Type I Interferonopathies in Childhood
title_full_unstemmed Type I Interferonopathies in Childhood
title_short Type I Interferonopathies in Childhood
title_sort type i interferonopathies in childhood
topic Invited Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175883/
https://www.ncbi.nlm.nih.gov/pubmed/37161741
http://dx.doi.org/10.4274/balkanmedj.galenos.2023.2023-4-78
work_keys_str_mv AT haslakfatih typeiinterferonopathiesinchildhood
AT kılıckonteelif typeiinterferonopathiesinchildhood
AT aslanesma typeiinterferonopathiesinchildhood
AT sahinsezgin typeiinterferonopathiesinchildhood
AT kasapcopurozgur typeiinterferonopathiesinchildhood